Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FABP4 gene therapy
- Development stage
- Preclinical
- Lead developer
- CuRsuS Bio
- Modality
- Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Electrical: Electroporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Acoustic/Optical: Sonoporation, laser photoporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Magnetic: Magnetofection → Physical Methods → Gene Addition/Replacement → Gene Therapies, Mechanical: Microinjection, microfluidics, gene gun → Physical Methods → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Pressure-driven: Hydrodynamic injection → Physical Methods → Gene Addition/Replacement → Gene Therapies
- Administration
- Injection
01
Overview
FABP4 gene therapy is a preclinical non-viral gene therapy being developed by CuRsuS Bio for the treatment of obesity and related metabolic disorders. The therapy utilizes a proprietary non-viral delivery platform, likely based on polymeric carriers, to transport short hairpin RNA (shRNA) specifically to adipose tissue. Once delivered, the shRNA mediates the knockdown of Fatty Acid Binding Protein 4 (FABP4), also known as adipocyte protein 2 (aP2). FABP4 is a key chaperone protein expressed in adipocytes and macrophages that regulates lipid transport and inflammatory signaling. By reducing FABP4 expression, the treatment aims to decrease adiposity, enhance insulin sensitivity, and mitigate systemic inflammation, offering a potential long-term therapeutic approach for weight management and metabolic health without the safety concerns associated with viral vectors.
- Other names
- CuRsuS Bio-Fatty acid-binding proteins-gene therapy-non-viral gene therapy-ObesityNon-viral FABP4 gene therapyshRNA-mediated FABP4 knockdown
02
Targets
FABP4 (Fatty acid-binding protein 4)
Beyond the preview
Go deeper on FABP4 gene therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FABP4 gene therapy.